Principles of laboratory assessment of drug abuse liability and implications for clinical development

Drug and Alcohol Dependence

Volumn 105, Issue SUPPL. 1, 2009, Pages

  Carter, Lawrence P ^a   Griffiths, Roland R ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abuse liability; Clinical trial; Drug abuse; Drug development; Drug discrimination; Self administration

Indexed keywords

ADDICTION; ANIMAL; BEHAVIORAL RESEARCH; DRUG SCREENING; HUMAN; METHODOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; RISK ASSESSMENT;

ANIMALS; BEHAVIORAL RESEARCH; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; RISK ASSESSMENT; SUBSTANCE-RELATED DISORDERS;

EID: 70449496024     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2009.04.003     Document Type: Review

References (106)

1. Ator N.A., Griffiths R.R. Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend. 2003, 70:S55-S72.
2. Ator N.A., Weerts E.M., Kaminski B.J., Kautz M.A., Griffiths R.R. Zaleplon and triazolam physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. Drug Alcohol Depend. 2000, 61:69-84.
3. Balster R.L., Bigelow G.E. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend. 2003, 70:S13-40.
4. Balster R.L., Schuster C.R. Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration. J. Exp. Anal. Behav. 1973, 20:119-129.
5. Bardo M.T., Bevins R.A. Conditioned place preference: what does it add to our preclinical understanding of drug reward?. Psychopharmacology 2000, 153:31-43.
6. Bickel W.K., Marsch L.A., Carroll M.E. Deconstructing relative reinforcing efficacy and situating the measures of pharmacological reinforcement with behavioral economics: a theoretical proposal. Psychopharmacology 2000, 153:44-56.
7. Bigelow G.E. Human drug abuse liability assessment: opioids and analgesics. Br. J. Addict. 1991, 86:1615-1628.
8. Bigelow G.E., Griffiths R.R., Liebson R., Kaliszak J.E. Double-blind evaluation of reinforcing and anorectic actions of weight control medications. Arch. Gen. Psychiatry 1980, 37:1118-1123.
9. Brady K.T., Lydiard R.B., Brady J.V. Assessing abuse liability in clinical trials. Drug Alcohol Depend. 2003, 70:S87-S95.
10. Busto U.E., Zawertailo L.A., Kaplan H.L., Sellers E.M. Identifying appropriate subjects for abuse liability studies using prestudy pharmacological testing. Can. J. Clin. Pharmacol. 1999, 6:103-110.
11. Carroll M.E., Stotz D.C., Kliner D.J., Meisch R.A. Self-administration of orally-delivered methohexital in rhesus monkeys with phencyclidine or pentobarbital histories: effects of food deprivation and satiation. Pharmacol. Biochem. Behav. 1984, 20:145-151.
12. Carter L.P., Flores L.R., Wu H., Chen W., Unzeitig A.W., Coop A., France C.P. The role of GABAB receptors in the discriminative stimulus effects of gamma-hydroxybutyrate in rats: time course and antagonism studies. J. Pharmacol. Exp. Ther. 2003, 305:668-674.
13. Carter L.P., Unzeitig A.W., Wu H., Chen W., Coop A., Koek W., France C.P. The Discriminative stimulus effects of gamma-hydroxybutyrate and related compounds in rats discriminating baclofen or diazepam: The role of GABA(B) and GABA(A) receptors. J. Pharmacol. Exp. Ther. 2004, 309:540-547.
14. Carter L.P., Richards B.D., Mintzer M.Z., Griffiths R.R. Relative abuse liability of GHB in humans: a comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neuropsychopharmacology 2006, 31:2537-2551.
15. Carter L.P., Griffiths R.R., Suess P.E., Casada J.H., Wallace C.L., Roache J.D. Relative abuse liability of indiplon and triazolam in humans: a comparison of psychomotor, subjective, and cognitive effects. J. Pharmacol. Exp. Ther. 2007, 322:749-759.
16. Chander G., Himelhoch S., Moore R.D. Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs 2006, 66:769-789.
17. Cicero T.J., Adams E.H., Geller A., Inciardi J.A., Muñoz A., Schnoll S.H., Senay E.C., Woody G.E. A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend. 1999, 57:7-22.
18. Collins G.T., Woods J.H. Drug and reinforcement history as determinants of the response-maintaining effects of quinpirole in the rat. J. Pharmacol. Exp. Ther. 2007, 323:599-605.
19. Colpaert F.C. Drug discrimination: no evidence for tolerance to opiates. Pharmacol. Rev. 1995, 47:605-629.
20. Comer S.D., Ashworth J.B., Foltin R.W., Johanson C.E., Zacny J.P., Walsh S.L. The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend. 2008, 96:1-15.
21. Czoty P.W., Reboussin B.A., Calhoun T.L., Nader S.H., Nader M.A. Long-term cocaine self-administration under fixed-ratio and second-order schedules in monkeys. Psychopharmacology 2007, 191:287-295.
22. Dart, R.C., Monitoring risk: postmarketing surveillance and signal detection. Drug Alcohol Depend., this issue.
23. Dasgupta, N., Schnoll, S.H., Signal detection in post-marketing surveillance for controlled substances. Drug Alcohol Depend., this issue.
24. de Wit H., Dudish S., Ambre J. Subjective and behavioral effects of diazepam depend on its rate of onset. Psychopharmacology 1993, 112:324-330.
25. de Wit H., Griffiths R.R. Testing the abuse liability of anxiolytics and hypnotic drugs in humans. Drug Alcohol Depend. 1991, 28:83-111.
26. Epstein D.H., Preston K.L., Jasinski D.R. Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biol. Psychol. 2006, 73:90-99.
27. Fantegrossi W.E., Harrington A.W., Eckler J.R., Arshad S., Rabin R.A., Winter J.C., Coop A., Rice K.C., Woods J.H. Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology 2005, 181:496-503.
28. Foltin R.W., Fischman M.W. Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Drug Alcohol Depend. 1991, 28:3-48.
29. France C.P., Weltman R.H., Koek W., Cruz C.M., McMahon L.R. Acute and chronic effects of ramelteon in rhesus monkeys (Macaca mulatta): Dependence liability studies. Behav. Neurosci. 2006, 120:535-541.
30. Fudala P.J., Johnson R.E. Development of opioid formulations with limited diversion and abuse potential. Drug Alcohol Depend. 2006, 83:S40-S47.
31. Fuller D.E., Hornfeldt C.S., Kelloway J.S., Stahl P.J., Anderson T.F. The Xyrem risk management program. Drug Saf. 2004, 27:293-306.
32. Gerak L.R., France C.P. Repeated administration of flumazenil does not alter its potency in modifying schedule-controlled behavior in chlordiazepoxide-treated rhesus monkeys. Psychopharmacology 1997, 131:64-70.
33. Gerak L.R., France C.P. Discriminative stimulus effects of flumazenil in untreated and in diazepam-treated rhesus monkeys. Psychopharmacology 1999, 146:252-261.
34. Goldberg S.R., Hoffmeister F., Schlichting U.U., Wuttke W. A comparison of pentobarbital and cocaine self-administration in rhesus monkeys: effects of dose and fixed-ratio parameter. J. Pharmacol. Exp. Ther. 1971, 179:277-283.
35. Griffiths R.R., Ator N.A. Benzodiazepine self-administration in animals and humans: a comprehensive literature review. NIDA Res. Monogr. 1980, 33:22-36.
36. Griffiths R.R., Balster R.L. Opioids: similarity between evaluations of subjective effects and animal self-administration results. Clin. Pharmacol. Ther. 1979, 25:611-617.
37. Griffiths R.R., Bigelow G.E., Ator N.A. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend. 2003, 70:S41-54.
38. Griffiths R.R., Bigelow G.E., Henningfield J.E. Similarities in animal and human drug-taking behavior. Advances in Substance Abuse 1980, 1-90. JAI Press, Inc., Greenwich, CT. N.K. Mello (Ed.).
39. Griffiths R.R., Lukas S.E., Bradford L.D., Brady J.V., Snell J.D. Self-injection of barbiturates and benzodiazepines in baboons. Psychopharmacology 1981, 75:101-109.
40. Griffiths R.R., Rush C.R., Puhala K. Validation of the multiple-choice procedure for investigating drug reinforcement in humans. Exp. Clin. Psychopharmacol. 1996, 4:97-106.
41. Griffiths R.R., Troisi J.R., Silverman K., Mumford G.K. Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behav. Pharmacol. 1993, 4:3-13.
42. Griffiths R.R., Weerts E.M. Benzodiazepine self-administration in humans and laboratory animals-implications for problems of long-term use and abuse. Psychopharmacology 1997, 134:1-37.
43. Grudzinskas C., Balster R.L., Gorodetzky C.W., Griffiths R.R., Henningfield J.E., Johanson C.E., Mansbach R.S., McCormick C.G., Schnoll S.H., Strain E.C., Wright C. Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report. Drug Alcohol Depend. 2006, 83(Suppl 1):S77-82.
44. Haertzen C.A. Development of scales based on patterns of drug effects, using the Addiction Research Center Inventory (ARCI). Physiological Reports 1966, 18:163-194.
45. Haney M. Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls. Addict. Biol. 2009, 14:9-21.
46. Haney M., Spealman R. Controversies in translational research: drug self-administration. Psychopharmacology 2008, 199:403-419.
47. Hart C.L., Haney M., Vosburg S.K., Rubin E., Foltin R.W. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008, 33:761-768.
48. Houtsmuller E.J., Fant R.V., Eissenberg T.E., Henningfield J.E., Stitzer M.L. Flavor improvement does not increase abuse liability of nicotine chewing gum. Pharmacol. Biochem. Behav. 2002, 72:559-568.
49. Hursh S.R., Winger G. Normalized demand for drugs and other reinforcers. J. Exp. Anal. Behav. 1995, 64:373-384.
50. Inciardi J.A., Surratt H.L., Kurtz S.P., Cicero T.J. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med. 2007, 8:171-183.
51. Jasinski D.R. Assessment of the abuse potentiality of morphine-like drugs (methods used in man). Drug Addiction I. Morphine, Sedative-Hypnotic and Alcohol Dependence. Handbook of Experimental Pharmacology 1977, vol. 45:197-258. Springer, Heidelberg.
52. Johnson M.W., Bickel W.K. Replacing relative reinforcing efficacy with behavioral economic demand curves. J. Exp. Anal. Behav. 2006, 85:73-93.
53. Johnson M.W., Suess P.E., Griffiths R.R. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch. Gen. Psychiatry 2006, 63:1149-1157.
54. Justinova Z., Tanda G., Redhi G.H., Goldberg S.R. Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology 2003, 169:135-140.
55. Katz N.P., Adams E.H., Benneyan J.C., Birnbaum H.G., Budman S.H., Buzzeo R.W., Carr D.B., Cicero T.J., Gourlay D., Inciardi J.A., Joranson D.E., Kesslick J., Lande S.D. Foundations of opioid risk management. Clin. J. Pain 2007, 23:103-118.
56. Koek W., Carter L.P., Lamb R.J., Chen W., Wu H., Coop A., France C.P. Discriminative stimulus effects of gamma-hydroxybutyrate (GHB) in rats discriminating GHB from baclofen and diazepam. J. Pharmacol. Exp. Ther. 2005, 314:170-179.
57. Koek W., Colpaert F.C., Vignon J. Effects of phencyclidine-type drugs in rats discriminating fentanyl from saline: pharmacological and behavioral characterization of intermediate levels of drug lever selection. J. Pharmacol. Exp. Ther. 1993, 264:746-756.
58. Leiderman D.B. Risk management of drug products and the FDA: evolution and context. Drug Alcohol Depend. 2009, 105(Suppl. 1):S9-S13.
59. Lile J.A., Stoops W.W., Glaser P.E., Hays L.R., Rush C.R. Acute administration of the GABA reuptake inhibitor tiagabine does not alter the effects of oral cocaine in humans. Drug Alcohol Depend. 2004, 76:81-91.
60. Mansbach R.S., Feltner D.E., Gold L.H., Schnoll S.H. Incorporating the assessment of abuse liability into the drug discovery and development process. Drug Alcohol Depend. 2003, 70:S73-85.
61. Martin W.R., Sloan J.W., Sapiro J.D., Jasinski D.R. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin. Pharmacol. Ther. 1971, 12:245-258.
62. McCabe S.E., Cranford J.A., West B.T. Trends in prescription drug abuse and dependence, co-occurrence with other substance use disorders, and treatment utilization: Results from two national surveys. Addict. Behav. 2008, 33:1297-1305.
63. McColl S., Sellers E.M. Research design strategies to evaluate the impact of formulations on abuse liability. Drug Alcohol Depend. 2006, 83:S52-62.
64. McMahon L.R., Li J.X., Carroll F.I., France C.P. Some effects of dopamine transporter and receptor ligands on discriminative stimulus, physiologic, and directly observable indices of opioid withdrawal in rhesus monkeys. Psychopharmacology 2009, 203:411-420.
65. McMillan D.E., Sun W.L., Hardwick W.C. Effects of drug discrimination history on the generalization of pentobarbital to other drugs. J. Pharmacol. Exp. Ther. 1996, 278:50-61.
66. McNair, D.M., Lorr, M., Droppleman, L.F., 1992. Edits manual for the profile of mood states. (Ed.), Edits/Educational and Industrial Testing Service, San Diego, CA.
67. Meisch R.A., Bell S.M., Lemaire G.A. Orally self-administered cocaine in rhesus monkeys: transition from negative or neutral behavioral effects to positive reinforcing effects. Drug Alcohol Depend. 1993, 32:143-158.
68. Mumford G.K., Evans S.M., Fleishaker J.C., Griffiths R.R. Alprazolam absorption kinetics affects abuse liability. Clin. Pharmacol. Ther. 1995, 57:356-365.
69. Mumford G.K., Rush C.R., Griffiths R.R. Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects. J. Pharmacol. Exp. Ther. 1995, 272:570-580.
70. Mumford G.K., Silverman K., Griffiths R.R. Reinforcing, subjective, and performance effects of lorazepam and diphenhydramine in humans. Exp. Clin. Psychopharmacol. 1996, 4:421-430.
71. Negus S.S., Rice K.C. Mechanisms of withdrawal-associated increases in heroin self-administration: pharmacologic modulation of heroin vs. food choice in heroin-dependent rhesus monkeys. Neuropsychopharmacology 2009, 34:899-911.
72. Panlilio L.V., Goldberg S.R. Self-administration of drugs in animals and humans as a model and an investigative tool. Addiction 2007, 102:1863-1870.
73. Preston K.L., Bigelow G.E. Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination. J. Pharmacol. Exp. Ther. 2000, 295:114-124.
74. Preston K.L., Wolf B., Guarino J.J., Griffiths R.R. Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability. J. Pharmacol. Exp. Ther. 1992, 262:707-720.
75. Rosenbaum J.F., Zajecka J. Clinical management of antidepressant discontinuation. J. Clin. Psychiatry 1997, 58:37-40.
76. Rowlett J.K., Lelas S., Spealman R.D. Transduction of the discriminative stimulus effects of zolpidem by GABA(A)/alpha1 receptors. Eur. J. Pharmacol. 2000, 406:R9-R10.
77. Rowlett J.K., Spealman R.D., Lelas S. Discriminative stimulus effects of zolpidem in squirrel monkeys: comparison with conventional benzodiazepines and sedative-hypnotics. J. Pharmacol. Exp. Ther. 1999, 291:1233-1241.
78. Rush C.R., Critchfield T.S., Troisi J.R., Griffiths R.R. Discriminative stimulus effects of diazepam and buspirone in normal volunteers. J. Exp. Anal. Behav. 1995, 63:277-294.
79. Rush C.R., Frey J.M., Griffiths R.R. Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology 1999, 145:39-51.
80. Schoedel K.A., Sellers E.M. Assessing abuse liability during drug development: changing standards and expectations. Clin. Pharmacol. Ther. 2008, 83:622-626.
81. Schuh L.M., Schuster C.R., Hopper J.A., Mendel C.M. Abuse liability assessment of sibutramine, a novel weight control agent. Psychopharmacology 2000, 147:339-346.
82. Schuster C.R., Johanson C.E. Relationship between the discriminative stimulus properties and subjective effects of drugs. Psychopharmacol. Ser. 1988, 4:161-175.
83. Schuster C.R., Thompson T. Self administration of and behavioral dependence on drugs. Annu. Rev. Pharmacol. 1969, 9:483-502.
84. Sevak R.J., Stoops W.W., Hays L.R., Rush C.R. Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans. J. Pharmacol. Exp. Ther. 2009, 328:1007-1018.
85. Sokolowska, M., Setnik, B., Jones, J., Johnson, F., Romach, M., Sellers, E., 2008. Validation of assessments for abuse liability trials. Presented at the College on Problems of Drug Dependence 70th Annual Meeting. <>. (abstract accessed Aug 8, 2008). http://www.cpdd.vcu.edu/.
86. Tallarida R.J. Interactions between drugs and occupied receptors. Pharmacol. Ther. 2007, 113:197-209.
87. Tanda G., Munzar P., Goldberg S.R. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat. Neurosci. 2000, 3:1073-1074.
88. Thompson T., Schuster C.R. Morphine self-administration, food-reinforced, and avoidance behaviors in rhesus monkeys. Psychopharmacologia 1964, 5:87-94.
89. Thomsen M., Caine S.B. Cocaine self-administration under fixed and progressive ratio schedules of reinforcement: comparison of C57BL/6J, 129X1/SvJ, and 129S6/SvEvTac inbred mice. Psychopharmacology 2006, 184:145-154.
90. U.S. Xyrem Multi-Center Study Groxup, 2003. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J. Toxicol. Clin. Toxicol. 41, 131-135.
91. U.S. Xyrem Multicenter Study Group, 2004. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 5, 119-123.
92. Walsh S.L., Nuzzo P.A., Lofwall M.R., Holtman J.R. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008, 98:191-202.
93. Walsh S.L., Preston K.L., Bigelow G.E., Stitzer M.L. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J. Pharmacol. Exp. Ther. 1995, 274:361-372.
94. Walsh S.L., Sullivan J.T., Preston K.L., Garner J.E., Bigelow G.E. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. J. Pharmacol. Exp. Ther. 1996, 279:524-538.
95. Wedin G.P., Hornfeldt C.S., Ylitalo L.M. The Clinical Development of γ-Hydroxybutyrate (GHB). Curr. Drug Saf. 2006, 1:99-106.
96. Weeks J.R. Experimental morphine addiction. Method for automatic intravenous injections in unrestrained rats. Science 1962, 138:143-144.
97. Weerts E.M., Ator N.A., Griffiths R.R. Comparison of the intravenous reinforcing effects of propofol and methohexital in baboons. Drug Alcohol Depend. 1999, 57:51-60.
98. Weerts, E.M., Goodwin, A.K., Kaminski, B.J., Griffiths, R.R., Ator, N.A., 2008. Self-administration of the gamma-hydroxybutyrate (GHB) prodrug gamma-butyrolactone (GBL) in baboons. Presented at the College on Problems of Drug Dependence 70th Annual Meeting. <>. (abstract accessed Aug 8, 2008). http://www.cpdd.vcu.edu/.
99. Winger G., Galuska C.M., Hursh S.R., Woods J.H. Relative reinforcing effects of cocaine, remifentanil, and their combination in rhesus monkeys. J. Pharmacol. Exp. Ther. 2006, 318:223-229.
100. Winter J.C. The stimulus properties of gamma-hydroxybutyrate. Psychopharmacology 1981, 73:372-375.
101. Woody G.E., Senay E.C., Geller A., Adamsd E.H., Inciardi J.A., Schnoll S., Muñoz A., Cicero T.J. An independent assessment of MEDWatch reporting for abuse/dependence and withdrawal from Ultram (tramadol hydrochloride). Drug Alcohol Depend. 2003, 72:163-168.
102. Woolverton W.L., Rowlett J.K., Winger G., Woods J.H., Gerak L.R., France C.P. Evaluation of the reinforcing and discriminative stimulus effects of gamma-hydroxybutyrate in rhesus monkeys. Drug Alcohol Depend. 1999, 54:137-143.
103. Wright C., Kramer E.D., Zalman M.A., Smith M.Y., Haddox J.D. Risk identification, risk assessment, and risk management of abusable drug formulations. Drug Alcohol Depend. 2006, 83:S68-76.
104. Wu L.T., Pilowsky D.J., Patkar A.A. Non-prescribed use of pain relievers among adolescents in the United States. Drug Alcohol Depend. 2008, 94:1-11.
105. Young A.M., Thompson T. Effects of naloxone on schedule-controlled behavior in morphine-maintained pigeons. J. Pharmacol. Exp. Ther. 1978, 205:236-245.
106. Zhang L., Walker E.A., Sutherland J., Young A.M. Discriminative stimulus effects of two doses of fentanyl in rats: pharmacological selectivity and effect of training dose on agonist and antagonist effects of mu opioids. Psychopharmacology 2000, 148:136-145.